Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Resolutions of the Ordinary General Meeting of Shareholders of Basilea
Pharmaceutica Ltd.
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, April 9, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
reported that shareholders approved all agenda items proposed at today's
Ordinary General Meeting of Shareholders for the financial year 2012. At the
meeting, 59.9 percent of Basilea's share capital was represented.
The shareholders approved the annual report, the financial statements and
consolidated financial statements for the business year 2012, and discharged the
members of the Board of Directors and Management. Shareholders also approved
carrying forward the accumulated deficit.
In addition, Dr. Martin Nicklasson was elected to the Board of Directors for a
term of three years. Basilea's Board of Directors now comprises seven non-
executive members: Dr. Martin Nicklasson, Mr. Hans-Beat Gürtler, Prof. Daniel
Lew, Dr. Thomas M. Rinderknecht, Mr. Domenico Scala, Mr. Steven D. Skolsky and
Dr. Thomas Werner. The Board of Directors elected Dr. Nicklasson as Chairman of
the Board and Domenico Scala as Vice-Chairman.
The shareholders re-elected PricewaterhouseCoopers AG, Basel, as Statutory
Auditors for the audit of the stand-alone and the consolidated financial
statements for the business year 2013.
Basilea's shareholders approved the proposal of HBM Healthcare Investments
(Cayman) Ltd., holding 24.97 percent of the company's shares, to distribute CHF
5.00 per share corresponding to approximately CHF 48 million from capital
contribution reserves to shareholders. The payment will be made on June
21, 2013. The last trading day to participate in the distribution will be
April 10, 2013. Starting from the ex-date of April 11, 2013, Basilea shares will
be traded without the right to participate in the distribution.
In his presentation to shareholders, Chief Executive Officer Ronald Scott
stated: "We achieved significant milestones in 2012 and successfully focused on
our core area of overcoming resistance in anti-infectives and oncology. The
company is uniquely positioned to potentially create significant value for our
shareholders as we move closer to the important milestones in the second half of
this year: the potential approval of our antibiotic ceftobiprole in Europe as
well as the first phase 3 results for our antifungal isavuconazole."
The Board and Management expressed their sincere thanks to the retiring Board
members Werner Henrich, Chairman since the company's inception, and Claude
Schreiner, Board Member since 2007, for their invaluable contributions.
Ronald Scott commented: "With his strategic vision, extensive experience in
deal-making and outstanding commitment, Werner Henrich has passionately worked
as our Chairman to build and grow the company for more than a decade. Claude
Schreiner's wide-ranging industry experience was instrumental in creating the
significant value of Toctino which we were able to achieve for shareholders
through our transaction with Stiefel/GSK last year."
With the addition of Dr. Nicklasson to the Board, the Board is convinced that
Basilea is well positioned to continue its path as one of the leading
biopharmaceutical companies addressing the growing medical need of drug
resistance.
About Basilea
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on
the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and
development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd., the Company focuses on innovative pharmaceutical products in
the therapeutic areas of bacterial infections, fungal infections and oncology,
targeting the medical challenge of rising resistance and non-response to current
treatment options.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.
For further information, please contact:
+-----------------------------+--------------------------------+
| Media Relations | Investor Relations |
+-----------------------------+--------------------------------+
| Peer Nils Schröder, PhD | Barbara Zink, PhD, MBA |
| Head Public Relations & | Head Corporate Development |
| Corporate Communications | |
| +41 61 606 1102 | +41 61 606 1233 |
| media_relations(at)basilea.com | investor_relations(at)basilea.com |
+-----------------------------+--------------------------------+
This press release can be downloaded from www.basilea.com.
Press release (PDF):
http://hugin.info/134390/R/1691712/555610.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
[HUG#1691712]
Unternehmensinformation / Kurzprofil:
Datum: 09.04.2013 - 17:14 Uhr
Sprache: Deutsch
News-ID 247430
Anzahl Zeichen: 6516
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd."
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
